{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:35:30Z","timestamp":1787502930804,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,11,25]],"date-time":"2012-11-25T00:00:00Z","timestamp":1353801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00246-012-0592-1","type":"journal-article","created":{"date-parts":[[2012,11,24]],"date-time":"2012-11-24T06:19:10Z","timestamp":1353737950000},"page":"984-990","source":"Crossref","is-referenced-by-count":41,"title":["Genetic and Clinical Determinants Influencing Warfarin Dosing in Children With Heart Disease"],"prefix":"10.1007","volume":"34","author":[{"given":"Nguyenvu","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Anley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,25]]},"reference":[{"key":"592_CR1","doi-asserted-by":"crossref","unstructured":"Anticoagulants in the secondary prevention of events in coronary thrombosis (ASPECT) research group (1994) effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction, Vol 343. Lancet, London pp 499\u2013503","DOI":"10.1016\/S0140-6736(94)91458-3"},{"key":"592_CR2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2011-08-372722","volume":"119","author":"TT Biss","year":"2012","unstructured":"Biss TT et al (2012) VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 119:868\u2013873","journal-title":"Blood"},{"key":"592_CR3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/blood-2005-01-0341","volume":"106","author":"L Bodin","year":"2005","unstructured":"Bodin L et al (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135\u2013140","journal-title":"Blood"},{"key":"592_CR4","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1046\/j.1538-7836.2003.00256.x","volume":"1","author":"M Bonduel","year":"2003","unstructured":"Bonduel M et al (2003) Acenocoumarol therapy in pediatric patients. J Thromb Haemost 1:1740\u20131743","journal-title":"J Thromb Haemost"},{"key":"592_CR5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-147-11-200712040-00006","volume":"147","author":"DS Budnitz","year":"2007","unstructured":"Budnitz DS et al (2007) Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 147:755\u2013765","journal-title":"Ann Intern Med"},{"key":"592_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","volume":"333","author":"SC Cannegieter","year":"1995","unstructured":"Cannegieter SC et al (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11\u201317","journal-title":"N Engl J Med"},{"key":"592_CR7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.clpt.6100316","volume":"83","author":"Y Caraco","year":"2008","unstructured":"Caraco Y, Blotnick S, Muszkat M (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83:460\u2013470","journal-title":"Clin Pharmacol Ther"},{"key":"592_CR8","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11239-010-0467-3","volume":"30","author":"JF Carlquist","year":"2010","unstructured":"Carlquist JF et al (2010) An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J Thromb Thrombolysis 30:358\u2013364","journal-title":"J Thromb Thrombolysis"},{"key":"592_CR9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2004-06-2111","volume":"105","author":"G D\u2019Andrea","year":"2005","unstructured":"D\u2019Andrea G et al (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105:645\u2013649","journal-title":"Blood"},{"key":"592_CR10","doi-asserted-by":"crossref","unstructured":"Guyatt GH et al. (2012) Executive summary: antithrombotic therapy and prevention of thrombosis. American college of chest physicians evidence-based clinical practice guidelines, 9th edn. Chest 141(2 Suppl):7S\u201347S","DOI":"10.1378\/chest.141.4.1129a"},{"key":"592_CR11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clpt.2003.10.001","volume":"75","author":"F Kamali","year":"2004","unstructured":"Kamali F et al (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75:204\u2013212","journal-title":"Clin Pharmacol Ther"},{"key":"592_CR12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2133\/dmpk.DMPK-10-NT-082","volume":"26","author":"Y Kato","year":"2011","unstructured":"Kato Y et al (2011) Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet 26:295\u2013299","journal-title":"Drug Metab Pharmacokinet"},{"key":"592_CR13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","volume":"360","author":"TE Klein","year":"2009","unstructured":"Klein TE et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753\u2013764","journal-title":"N Engl J Med"},{"key":"592_CR14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jmg.2005.040410","volume":"43","author":"T Li","year":"2006","unstructured":"Li T et al (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 43:740\u2013744","journal-title":"J Med Genet"},{"key":"592_CR15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/14622416.9.5.511","volume":"9","author":"NA Limdi","year":"2008","unstructured":"Limdi NA et al (2008) Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment, and maintenance among European-Americans and African-Americans. Pharmacogenomics 9:511\u2013526","journal-title":"Pharmacogenomics"},{"key":"592_CR16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-008-0584-5","volume":"65","author":"JD Lindh","year":"2009","unstructured":"Lindh JD et al (2009) Influence of CYP2C9 genotype on warfarin dose requirements\u2013a systematic review and meta-analysis. Eur J Clin Pharmacol 65:365\u2013375","journal-title":"Eur J Clin Pharmacol"},{"issue":"6 Suppl","key":"592_CR17","doi-asserted-by":"crossref","first-page":"887S","DOI":"10.1378\/chest.08-0762","volume":"133","author":"P Monagle","year":"2008","unstructured":"Monagle P et al (2008) Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):887S\u2013968S","journal-title":"Chest"},{"key":"592_CR18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood-2011-07-365502","volume":"119","author":"C Moreau","year":"2012","unstructured":"Moreau C et al (2012) Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 119:861\u2013867","journal-title":"Blood"},{"key":"592_CR19","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1182\/blood-2010-05-283861","volume":"116","author":"U Nowak-Gottl","year":"2010","unstructured":"Nowak-Gottl U et al (2010) In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood 116:6101\u20136105","journal-title":"Blood"},{"key":"592_CR20","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","volume":"352","author":"MJ Rieder","year":"2005","unstructured":"Rieder MJ et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285\u20132293","journal-title":"N Engl J Med"},{"key":"592_CR21","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2217\/14622416.9.9.1331","volume":"9","author":"H Schelleman","year":"2008","unstructured":"Schelleman H, Limdi NA, Kimmel SE (2008) Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 9:1331\u20131346","journal-title":"Pharmacogenomics"},{"key":"592_CR22","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","volume":"106","author":"EA Sconce","year":"2005","unstructured":"Sconce EA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329\u20132333","journal-title":"Blood"},{"key":"592_CR23","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V94.9.3007","volume":"94","author":"W Streif","year":"1999","unstructured":"Streif W et al (1999) Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 94:3007\u20133014","journal-title":"Blood"},{"key":"592_CR24","doi-asserted-by":"crossref","unstructured":"Stroke prevention in atrial fibrillation III randomised clinical trial (1996) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation, Vol 348. Lancet, London pp 633\u2013638","DOI":"10.1016\/S0140-6736(96)03487-3"},{"key":"592_CR25","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","volume":"5","author":"F Takeuchi","year":"2009","unstructured":"Takeuchi F et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433","journal-title":"PLoS Genet"},{"key":"592_CR26","doi-asserted-by":"crossref","unstructured":"The stroke prevention in atrial fibrillation investigators (1996) bleeding during antithrombotic therapy in patients with atrial fibrillation, Vol 156. Arch Intern Med, Chicago pp 409\u2013416","DOI":"10.1001\/archinte.156.4.409"},{"key":"592_CR27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00439-006-0260-8","volume":"121","author":"M Wadelius","year":"2007","unstructured":"Wadelius M et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23\u201334","journal-title":"Hum Genet"},{"key":"592_CR28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","volume":"113","author":"M Wadelius","year":"2009","unstructured":"Wadelius M et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784\u2013792","journal-title":"Blood"},{"key":"592_CR29","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/j.thromres.2009.11.020","volume":"125","author":"PS Wells","year":"2010","unstructured":"Wells PS et al (2010) A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res 125:e259\u2013e264","journal-title":"Thromb Res"},{"key":"592_CR30","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1373\/clinchem.2006.078139","volume":"53","author":"Y Zhu","year":"2007","unstructured":"Zhu Y et al (2007) Estimation of warfarin maintenance dose based on VKORC1 (-1639 G\u00a0>\u00a0A) and CYP2C9 genotypes. Clin Chem 53:1199\u20131205","journal-title":"Clin Chem"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-012-0592-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00246-012-0592-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-012-0592-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T15:18:01Z","timestamp":1594912681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00246-012-0592-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,25]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s00246-012-0592-1","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,25]]}}}